'Microbiological finding' sees a halt to GSK/Anacor's antibiotic trials
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has voluntarily "paused" enrolment into current Phase I and Phase II trials of GSK2251052 (GSK '052) "due to a recently identified microbiological finding in a small number of patients in the Phase IIb trial of GSK '052 for the treatment of complicated urinary tract infections (cUTI)", its partner Anacor Pharmaceuticals said.